Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).

The Long Run with Luke Timmerman

Timmerman Report

Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease

DEC 15, 202567 MIN
The Long Run with Luke Timmerman

Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease

DEC 15, 202567 MIN

Description

Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).